PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 8, 2026Oral Diseases2 citations

Combined Effects of Romosozumab and Zoledronate on the Development of Osteonecrosis of the Jaw

View Full Paper
HPHae‐Seo ParkSKShihyun KimSASeo‐Yeong An

Key Points

  • This research investigates the combined impact of romosozumab and zoledronate on osteonecrosis of the jaw.
  • Examined the sequential administration of romosozumab and zoledronate.
  • Monitored the risk of medication-related osteonecrosis of the jaw (MRONJ).
  • Analyzed clinical implications for treatment protocols.
  • Sequential treatment may worsen the risk of developing osteonecrosis of the jaw.
  • Highlights the necessity for cautious clinical application of these therapies.

Abstract

Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Park et al. (2026) studied this question.

synapsesocial.com/papers/69d5f09e74eaea4b11a7a0eehttps://doi.org/10.1111/odi.70331
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Risk of medication-related osteonecrosis of the jaw during romosozumab treatment2026
  2. 2The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracture2025
  3. 3The preclinical discovery and development of romosozumab for the treatment of people with severe osteoporosis who are at high risk of fracture2025
  4. 4Sequential Anabolic and Antiresorptive Treatment Promotes Medication‐Related Osteonecrosis of the Jaw in Mice2026
  5. 5Secondary Publication: Use of Romosozumab Against Osteoporosis2025